Email Updates

You are here

AVAC's Blog: P-Values

  • In this time of COVID-19, new information and new questions arise daily with implications for global health advocacy and for the HIV response at large. In the midst of this, HIV research has taken some major steps forward as well. AVAC has produced a number resources to keep you informed and guide your advocacy on all these issues.

    May 21, 2020
    AVAC
  • We are writing with breaking PrEP news—data now show that bi-monthly injections of long-acting cabotegravir (CAB-LA) appears to be safe and effective in preventing HIV in cisgender men and transgender women who have sex with men.

    May 18, 2020
    AVAC
  • This HIV Vaccine Awareness Day a global audience is fixated on the need for vaccines. The COVID-19 pandemic has people struggling to understand the science, the development process and the necessity of a vaccine. Taking in these lessons is no less vital for HIV. AVAC’s new report, Five “P”s to Watch: Platforms, process, partnerships, payers and participatory practices that drive vaccine development, connects these key issues and lays out how HIV vaccine research is making the search for a COVID-19 vaccine faster, smarter and more inclusive.

    May 18, 2020
    AVAC
  • A new episode of AVAC’s Px Pulse podcast is ready for download! We take a comprehensive look at the intersection of HIV and COVID-19.

    May 14, 2020
    AVAC
  • This HIV Vaccine Awareness Day (HVAD), May 18, 2020, is like no other before. HIV and COVID-19 each present a vivid picture of the need for the vaccine enterprise. A durable, sustainable end to any epidemic depends on a vaccine. HVAD is a day to call attention to the still-urgent need for an HIV vaccine, take stock of progress, recognize the incalculable contributions of trial participants and researchers—and, this year, to explain how work in HIV has created the foundation for the unprecedented speed of COVID-19 vaccine development.

    May 12, 2020
    AVAC
  • Six months? A year? Longer? Never? How long until there’s a vaccine against COVID-19? How is COVID vaccine research moving so quickly? How do HIV vaccine and COVID-19 vaccine research relate and inform each other? Jon Cohen, one of the leading journalists covering both HIV and COVID recently joined us for a webinar.

    May 7, 2020
    AVAC
  • The WHO Working Group has articulated important criteria for assessing a challenge study, but we believe that they left out the most important one: Until there is an approved treatment, a challenge trial with a potentially fatal and as-yet untreatable pathogen is unacceptable.

    May 7, 2020
    AVAC
    Treatment Action Group
  • To make headway against both HIV and COVID-19, we must demand commitment to science and evidence, collaboration and innovation. And we must work together with undaunted commitment.

    May 5, 2020
    General
    AVAC
  • For women all over the world, getting the products and services they need and want for HIV prevention and for sexual & reproductive health (SRH) are mired in challenges – and COVID-19 is intensifying the struggle. Siloed care, stock outs, and too little input from women themselves on the design of programs and products are among the long-standing barriers to women’s healthcare, and COVID-19 exacerbates these difficulties. AVAC is expanding our partnerships and programs to meet these challenges.

    April 30, 2020
    AVAC
  • New COVID-19 mathematical models are emerging to predict trends in new infections and deaths in cities, countries and globally. These models can forecast medical supply shortages, and influence policy makers and investment of resources. Strengthening our understanding of current models, how they are developed, and their limitations, allows us to better apply modeling to public health policies and programs.

    April 28, 2020
    AVAC

Pages